Article

ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypes

2023-09-19

Abstract excerpt

Breast cancer is a leading cause of female mortality and despite advancements in diagnostics and personalized therapeutics, metastatic disease largely remains incurable due to drug resistance. Fortunately, identification of mechanisms of therapeutic resistance have rapidly transformed our understanding of cancer evasion and is enabling targeted treatment regimens. When the druggable estrogen receptor (ER, ESR1 ),...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1cdbb88c-9977-5de3-ace3-b7c8739c2f66
DOI: 10.1101/2023.09.18.558175

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypesDOI 10.1101/2023.09.18.558175Read

ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.Semantic proximity Read

Molecular characterization of ESR1 variants in breast cancer.Semantic proximity Read

Fusion Genes in Breast Cancer.Semantic proximity Read

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Semantic proximity Read

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.Semantic proximity Read

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.Semantic proximity Read

Molecular Characterization of ESR1 Variants in Breast CancerSemantic proximity Read

<scp>Fusion‐associated</scp>carcinomas of the breast: Diagnostic, prognostic, and therapeutic significanceSemantic proximity Read

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activationSemantic proximity Read

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancerSemantic proximity Read

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasisSemantic proximity Read

<i>ESR1</i> fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypes

Abstract excerpt

Topics

Identifiers and source

Related research